Angiogenesis and antiangiogenic cancer therapy;Angiogeneze a antiangiogenní terapie u nádorů

Vnitrni Lekarstvi

Volumn 50, Issue 12, 2004, Pages 930-938

  Pour, Luděk ^a   Hajek R ^a   Buchler, T ^a   Maisnar, V ^b   Smolej, L ^b  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Angiogenesis; Antiangiogenic therapy; Cancer

Indexed keywords

2 METHOXYESTRADIOL; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 4 DEDIMETHYLAMINOSANCYCLINE; AE 941; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BEVACIZUMAB; CGS 27023A; DALTEPARIN; ENDOSTATIN; ENZASTAURIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GENISTEIN; LONAFARNIB; MARIMASTAT; MONOCLONAL ANTIBODY; PENICILLAMINE; PRINOMASTAT; PROTEIN FARNESYLTRANSFERASE INHIBITOR; REBIMASTAT; RIBOZYME; SQUALAMINE; SURAMIN; TANOMASTAT; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VATALANIB; ZK 22584;

ANGIOGENESIS; CANCER; CANCER THERAPY; CLINICAL TRIAL; DRUG MECHANISM; FETUS DEVELOPMENT; GENE OVEREXPRESSION; HUMAN; METASTASIS; METASTASIS POTENTIAL; NEOVASCULARIZATION (PATHOLOGY); OVARY CYCLE; REGULATORY MECHANISM; REVIEW; TISSUE GROWTH; TISSUE REPAIR; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 11144239741     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. th annual meeting. Abstract 2199
2. Adam, Z., Pour, L., Svobodnik, A. et al.: Kvalita života a tolerance uržovací léčby u pacienů s mnohočetným myelomem. Vnitř. Lék., 48, 2002, 216-229
3. Adam, Z., Krejčí, M., Bačovský, J. et al.: Léčba mnočetného myelomu vysokodávkovanou chemoterapií a transplantací autologních periferních kmenových hematopoetických buněk a následují cí udržovací léčbou interferonem alfa a dexamethasonem. Vnitř. Lék., 44, 1998, 400-408
4. Adams, J.: Proteasome inhibition in cancer: development of PS-341. Semin. Oncol., 28, 2001, 613-619
5. Aguayo, A., Kantarjian, H. M., Estey, E. H. et al.: Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer, 95, 2002, 1923-1930
6. Awada, A., Eskens, F. A., Piccart, M. et al.: Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours. Eur. J. Cancer, 38, 2002, 2272-2278
7. Barille, S., Akhoundi, C., Collette, M. et al.: Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood, 90, 1997, 1649-1655
8. th annual meeting, Abstract 789
9. Bellamy, W. T.: Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Semin. Oncol., 28, 2001, 551-559
10. Bergsland, E., Hurwitx, H., Fehrenbacher, L. et al.: A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol., 28, 2000, Abstract 939
11. Berlin, J., Tutsch, K. D., Arzoomanian, R. Z. et al.: Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: toxicity, bioavailability and the effect of food. Clin. Cancer Res., 8, 2002, 86-94
12. Brehm, S.: Angiogenesis and Cancer Control: From Concept to Therapeutic Trial. Cancer Control, 6, 1999, 436-458
13. Capillo, M., Mancuso, P., Gobbi, A. et al.: Continuous Infusion of Endostatin Inhibits Differentiation, Mobilization, and Clonogenic Potential of Endothelial Cell Progenitors. Clin. Cancer Res., 9, 2003, 377-382
14. Cianfrocca, M., Cooley, T. P., Lee, J. Y. et al.: Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J. Clin. Oncol., 20, 2002, 153-159
15. Cox, C., Teknos, T. N., Barrios, M. et al.: The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma. Laryngoscope, 11, 2001, 696-701
16. D'Amato, R. J., Lentzsch, S., Anderson, K. C. et al.: Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma. Semin. Oncol., 28, 2001, 597-601
17. DeVore, R. F., Fehrenbacher, L., Herbst, R. S. et al.: A randomized phase II trial comparing Rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IVNSCLC. Proc. Am. Soc. Clin. Oncol., 19, 2000, Abstract 1896
18. Dhar, D. K., Ono, T., Yamanoi, A. et al.: Serum endostatin predicts tumor vascularity in hepatocellular carcinoma. Cancer, 95, 2002, 2188-2195
19. Dy, G. K., Adjei, A. A.: Farnesyltransferase inhibitors in breast cancer therapy. Cancer Invest., Suppl. 2., 20, 2002, 30-37
20. Eppenberger, U., Kueng, W., Schlaepi, J. M. et al.: Markers of tumor angiogenesis and proteolysis independently define high an low risk subsets of node negative breast cancer patients. J. Clin. Oncol., 20, 1998, 3129-3136
21. Ergun, S., Kilic, N., Wurmbach, J. H. et al.: Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes. Angiogenesis, 4, 2001, 93-206
22. Falardeau, P., Champagne, P., Poyet, P. et al.: Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin. Oncol., 28, 2001, 620-625
23. Foldyna, D., Kamelander, J., Krejčí, M. et al.: Žádoucí a nežádoucí účinky léčby thalidomidem u pacienů s mnohočetným myelomem. Vnitř. Lék., 49, 2003, 859-868
24. Folkman, J.: Angiogenesis-dependent diseases. Semin. Oncol., 28, 2001, 536-542
25. Folkman, J.: Role of angiogenesis in tumor growth and metastasis. Semin. Oncol., 20, 2002, 15-18
26. Folkman, J.: Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 18, 1971, 1182-1186
27. Giles, F. J.: The emerging role of angiogenesis inhibitors in hematologic malignancies. Oncology, 5, 2002, 23-29
28. Giles, F. J.: New drugs in acute myeloid leukemia. Curr. Oncol. Rep., 4, 2002, 369-374
29. Gingras, D., Batist, G., Beliveau, R.: AE-941 (Neovastat): a novel multifunctional antiangiogenic compound. Expert Rev. Anticancer Ther., 3, 2001, 341-347
30. Gordon, M. S., Margolin, K., Talpaz, M. et al.: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol., 19, 2001, 843-850
31. Heath, E. I., O'Reilly, S., Humphrey, R. et al.: Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors. Cancer Chemother. Pharmacol., 48, 2001, 269-274
32. Hajek, R., Adam, Z., Krivanova, A. et al.: Current role of immunotherapy in multiple myeloma. Acta Med. Austriaca, 25, 1998, 79-85
33. Hajitou, A., Grignet, C., Devy, L. et al.: The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J., 16, 2002, 1802-1804
34. Howe, L. R., Subbaramaiah, K., Patel, J. et al.: Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res., 62, 2002, 5405-5407
35. Chisi, J. E., Briscoe, C. V., Ezan, E. et al.: Captopril inhibits in vitro and in vivo the proliferation of primitive haematopoietic cells induced into cell cycle by cytotoxic drug administration or irradiation but has no effect on myeloid leukaemia cell proliferation. Br. J. Haematol., 109, 2000, 563-570
36. Ishigami, S. I., Arii, S., Furutani, M., et al.: Predictive Value of VEGF in metastasis and prognosis of human colorectal cancer. Br. J. Cancer, 78, 1998, 1379-1384
37. Kabbinavar, F., Hurwitz, H. I., Fehrenbacher, L. et al.: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol., 21, 2003, 60-65
38. Karp, J. E., Lancet, J. E., Kaufmann, S. H. et al.: Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood, 97, 2001, 3361-3369
39. Katano, K., Kondo, A., Safaei, R. et al.: Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res., 62, 2002, 6559-6565
40. Klener, P.: Perspektivní možnosti v protiná dorové chemoterapii. ČLČ, 140, 2001, 605-610
41. Klener, P.: Klinická onkologie. Galén, Praha 2002; vybrané kapitoly
42. Lattime, E. C., Gerson, S. L.: Gene therapy of cancer, second edition. Academic Press, San Diego 2002, 405-432
43. Lee Rosen, S.: Clinical Experience With Angiogenesis Signaling Inhibitors: Focus on Vascular Endothelial Growth Factor (VEGF) Blockers. Cancer Control, 9, 2002, 36-44
44. Linder-Stragliotto, C., Strander, H., Munck-Wikland, E.: Low levels of endostatin in the urine from patients with malignant disease. Tumour Biol., 23, 2002, 222-227
45. Levitt, N. C., Eskens, F. A., O'Byrne, K. J. et al.: Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin. Cancer Res., 7, 2001, 1912-1922
46. Lin, B., Podar, K., Gupta, D. et al.: The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res., 62, 2002, 5019-5026
47. th annual meeting, Abstract 3119
48. Lokeshwar, B. L., Selzer, M. G., Zhu, B. Q. et al.: Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model. Int. J. Cancer, 98, 2002, 297-309
49. Marriott, J. B., Clarke, I. A., Dredge, K. et al.: Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin. Exp. Immunol., 1, 2002, 75-84
50. Moehler, T. M., Neben, K., Goldschmidt, H.: Angiogenesis in hematologic malignancies. Ann. Hematol. 80, 2001, 695-705
51. Moser, T. L., Stack, M. S., Wahl, M. L.: The mechanism of action of angiostatin: can you teach an old dog new tricks? Thromb. Haemost., 83, 2002, 394-401
52. Mysliwski, A., Koszalka, P., Bigda, J.: Complete remission of Bomirski Ab amelanotic melanoma in hamsters treated with the angiogenesis inhibitor TNP-470. Neoplasma, 49, 2002, 319-322
53. Naglich, J. G., Jure-Kunkel, M., Gupta, E. et al.: Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res., 61, 2001, 8480-8485
54. Ohta, Y., Endo, Y., Tanaka, M. et al.: Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin. Cancer Res., 2, 1996, 1411-1416
55. Orpana, A., Salven, P.: Angiogenic and lymphangiogenic molecules in hematological malignancies. Leuk. Lymphoma, 43, 2002, 219-224
56. Paley, P. J., Staskus, K. A., Gebhard, K. et al.: VEGF expression in early stage ovarian carcinoma. Cancer, 80, 1997, 98-106
57. Pan, Q., Kleer, C. G., van Golen, K. L. et al.: Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res., 62, 2002, 4854-4859
58. Patel, S. R., Jenkins, J., Papadopolous, N. et al.: Pilot study of vitaxin - an angiogenesis inhibitor - in patients with advanced leiomyosarcomas. Cancer, 92, 2001, 1347-1348
59. Posey, J. A., Khazaeli, M. B., DelGrosso, A. et al.: A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biother. Radiopharm., 16, 2001, 125-132
60. Rajkumar, S. V., Kyle, R. A.: Angiogenesis in multiple myeloma. Semin. Oncol., 28, 2001, 560-564
61. Ribatti, D., Vacca, A., Iurlaro M. et al.: Human recombinant interferon alpha-2a inhibits angiogenesis of chick area vasculosa in shell-less culture. Int. J. Microcirc. Clin. Exp., 16, 1996, 165-169
62. th annual meeting, Abstract 386
63. Richardson, P. G., Schlossman, R. L., Weller, E. et al.: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 100, 2002, 3063-3067
64. th annual meeting, Abstract 1308
65. Rosemurgy, A., Harris, J., Langleben, J. et al.: Marimastat in patients with advanced panceatic cancer: a dose finding study. Am. J. Clin. Oncol., 22, 1999, 247-252
66. Ryska, A., Hovorkova, E., Ludvikova, M.: Angiogeneze u nádorů, část II. Čes.-slov. Patol., 36, 2000, 71-80
67. Ryska, A.: Angiognese u nádorů, část I. Čes.-slov. Patol., 36, 2000, 26-31
68. Scappaticci, F. A.: Mechanisms and future directions for angiogenesis-based cancer therapies. J. Clin. Oncol., 20, 2002, 3906-3927
69. Scappaticci, F. A., Contreras, A., Smith, R. et al.: Statin-AE: a novel angiostatin-endostatin fusion protein with enhanced antiangiogenic and antitumor activity. Angiogenesis, 4, 2001, 263-268
70. Sen, C. K., Khanna, S., Venojarvi, M. et al.: Copper-induced vascular endothelial growth factor expression and wound healing. Am. J. Physiol. Heart Circ. Physiol., 282, 2002, 1821-1827
71. Sepherd, F. A., Giaccone, G., Seymour, L. et al.: Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the national cancer institute of Canada-clinical trials group and the European organization for research and treatment of cancer. J. Clin. Oncol., 20, 2002, 4434-4439
72. Sledge, G., Miller, K., Novotny, W. et al.: A phase II trial of single-agent Rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) in patients with relapsed metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 2000, Abstract 5C
73. Stadler, W. M., Kuzel, T., Shapiro, C. et al.: Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J. Clin. Oncol., 17, 1999, 2541-2545
74. Stratton, M. S., Alberts, D. S.: Current application of selective COX-2 inhibitors in cancer prevention and treatment. Oncology, 16, 2002, 37-51
75. Taga, T., Suzuki, A., Gonzalez-Gomez, I. et al.: The alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer, 90, 2002, s.690-697
76. Tamura, M., Ohta, Y., Nakamura, H. et al.: Diagnostic value of plasma vascular endothelial growth factor as a tumor marker in patients with non-small cell lung cancer. Int. J. Biol. Markers, 17, 2002, 275-279
77. Thomas, J. P., Arzoomanian, R. Z., Alberti, D. et al.: Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol., 21, 2003, 223-231
78. Trifan, O. C., Durham, W. F., Salazar, V. S. et al.: Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res., 62, 2002, 5778-5784
79. Tulpule, A., Scadden, D. T., Espina, B. M. et al.: Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. J. Clin. Oncol., 18, 2000, 716-723
80. Vacca, A., Ribatti, D., Roccaro, A. M. et al.: Bone marrow angiogenesis in patients with active multiple myeloma. Semin. Oncol., 28, 2001, 543-550
81. Vacca, A., Ribatti, D., Presta, M. et al.: Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood, 93, 1999, 544-552
82. te Velde, E. A., Vogten, J. M., Gebbink, M. F. et al.: Enhanced antitumour efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model. Br. J. Surg., 10, 2002, 1302-1309
83. Voest, E., D'Amore, P.: Tumor angiogenesis and microcirculation. Marcel Dekker AG, New York, 2001, 623 s.
84. www.cancer.gov/clinicaltrials/developments